How apoptosis and epithelial-to-mesenchymal transition are nested in EGFR inhibitors resistance in lung cancer.
作者信息
Garinet Simon, Didelot Audrey, Garelli Elena, Pallier Karine, Blons Hélène, Legras Antoine
机构信息
INSERM UMR-S1147, CNRS SNC 5014, Saints-Pères Research Center, 45 rue des Saints-Pères Paris-Descartes University, Sorbonne Paris Cité University, Paris 75006, France.
Molecular Biology Department, Georges Pompidou European Hospital, Assistance Publique - Hôpitaux de Paris, Paris 75015, France.
出版信息
J Thorac Dis. 2019 Jan;11(1):47-49. doi: 10.21037/jtd.2018.12.117.
Abstract
摘要
相似文献
1
How apoptosis and epithelial-to-mesenchymal transition are nested in EGFR inhibitors resistance in lung cancer.
J Thorac Dis. 2019 Jan;11(1):47-49. doi: 10.21037/jtd.2018.12.117.
2
Cancer-associated fibroblasts promote epithelial-mesenchymal transition and EGFR-TKI resistance of non-small cell lung cancers via HGF/IGF-1/ANXA2 signaling.
Biochim Biophys Acta Mol Basis Dis. 2018 Mar;1864(3):793-803. doi: 10.1016/j.bbadis.2017.12.021. Epub 2017 Dec 16.
3
Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer.
Oncotarget. 2015 Dec 29;6(42):44332-45. doi: 10.18632/oncotarget.6293.
4
Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo.
Eur J Cancer. 2013 Nov;49(16):3559-72. doi: 10.1016/j.ejca.2013.07.007. Epub 2013 Aug 2.
5
Concurrent epidermal growth factor receptor T790M secondary mutation and epithelial-mesenchymal transition in a lung adenocarcinoma patient with EGFR-TKI drug resistance.
Thorac Cancer. 2017 Nov;8(6):693-697. doi: 10.1111/1759-7714.12484. Epub 2017 Aug 8.
6
Epithelial-to-mesenchymal transition (EMT) causing acquired resistance to afatinib in a patient with epidermal growth factor receptor ()-mutant lung adenocarcinoma.
J Thorac Dis. 2018 Jul;10(7):E560-E563. doi: 10.21037/jtd.2018.06.122.
7
Clinical significance of epidermal growth factor receptor tyrosine kinase inhibitors: sensitivity and resistance.
Respir Investig. 2014 Nov;52(6):348-56. doi: 10.1016/j.resinv.2014.10.002. Epub 2014 Oct 31.
8
The role of epithelial to mesenchymal transition in resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Transl Lung Cancer Res. 2016 Apr;5(2):172-82. doi: 10.21037/tlcr.2016.04.07.
9
[Research Progress of the Role of EMT in EGFR-TKIs Resistance
of Non-small Cell Lung Cancer].
Zhongguo Fei Ai Za Zhi. 2018 Dec 20;21(12):907-911. doi: 10.3779/j.issn.1009-3419.2018.12.08.
10
Epithelial-to-mesenchymal transition and its role in EGFR-mutant lung adenocarcinoma and idiopathic pulmonary fibrosis.
Pathol Int. 2017 Aug;67(8):379-388. doi: 10.1111/pin.12553. Epub 2017 Jul 5.
引用本文的文献
1
The pan-cancer landscape of crosstalk between epithelial-mesenchymal transition and immune evasion relevant to prognosis and immunotherapy response.
NPJ Precis Oncol. 2021 Jun 22;5(1):56. doi: 10.1038/s41698-021-00200-4.
2
Epithelial-to-mesenchymal transition and drug resistance: transitioning away from death.
J Thorac Dis. 2019 Jun;11(6):E82-E85. doi: 10.21037/jtd.2019.06.11.
本文引用的文献
1
Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer.
Oncogene. 2019 Jan;38(5):656-670. doi: 10.1038/s41388-018-0482-y. Epub 2018 Aug 31.
2
Distinguishing mechanisms underlying EMT tristability.
Cancer Converg. 2017;1(1):2. doi: 10.1186/s41236-017-0005-8. Epub 2017 Nov 1.
3
Epithelial-to-Mesenchymal Transition Antagonizes Response to Targeted Therapies in Lung Cancer by Suppressing BIM.
Clin Cancer Res. 2018 Jan 1;24(1):197-208. doi: 10.1158/1078-0432.CCR-17-1577. Epub 2017 Oct 19.
4
Epithelial-to-Mesenchymal Transition and MicroRNAs in Lung Cancer.
Cancers (Basel). 2017 Aug 3;9(8):101. doi: 10.3390/cancers9080101.
5
Therapeutic Targeting of Epithelial Plasticity Programs: Focus on the Epithelial-Mesenchymal Transition.
Cells Tissues Organs. 2017;203(2):114-127. doi: 10.1159/000447238. Epub 2017 Feb 20.
6
Targeting the miR-200c/LIN28B axis in acquired EGFR-TKI resistance non-small cell lung cancer cells harboring EMT features.
Sci Rep. 2017 Jan 13;7:40847. doi: 10.1038/srep40847.
7
Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers.
Clin Cancer Res. 2017 Jun 1;23(11):2891-2904. doi: 10.1158/1078-0432.CCR-16-1025. Epub 2016 Nov 30.
8
Tumor Budding: The Name is EMT. Partial EMT.
J Clin Med. 2016 Apr 29;5(5):51. doi: 10.3390/jcm5050051.
9
O-GlcNAc transferase inhibitors: current tools and future challenges.
Biochem Soc Trans. 2016 Feb;44(1):88-93. doi: 10.1042/BST20150189.
10
PRMT1 Is a Novel Regulator of Epithelial-Mesenchymal-Transition in Non-small Cell Lung Cancer.
J Biol Chem. 2015 May 22;290(21):13479-89. doi: 10.1074/jbc.M114.636050. Epub 2015 Apr 6.
Zotero 插件